孕妇HIV感染筛查:美国预防服务工作组更新证据报告与系统综述
本系统综述更新2012年证据,纳入62项研究(含29项新研究),未发现产前筛查与不筛查对母婴传播风险影响的直接证据;新证据确认联合抗逆转录病毒治疗(ART)可高效降低母婴传播风险,孕早期启动时传播率低于1%,但含增效蛋白酶抑制剂的方案与早产风险增加相关。
要点
- 联合ART降低HIV母婴传播高度有效,孕早期启动时传播率0%-0.4%。
- 产前筛查与不筛查对母婴传播风险的影响仍无直接证据。
- 含增效蛋白酶抑制剂的产前联合ART与早产风险增加相关(范围14.4%-26.1%)。
核心结论
- 联合ART在降低HIV母婴传播风险方面高度有效,孕期使用某些ART方案与伤害风险增加相关,可能通过选择ART方案减轻。
研究设计与样本
- 系统综述更新2012年综述,检索Ovid MEDLINE、Cochrane对照试验中心注册库和Cochrane系统综述数据库2012年至2018年6月,监测至2019年1月,纳入62项研究(含29项新研究),研究对象为13岁及以上孕妇。
主要发现
- 仍无直接证据比较产前筛查与不筛查对HIV母婴传播风险、母婴临床结局或重复或替代筛查策略检出率的影响。
- 新证据确认联合ART高度有效降低母婴传播风险,部分新队列研究报告孕早期启动联合ART时母婴传播率低于1%(孕早期开始为0%-0.4%;孕早期后开始或未报告启动时间者为0.4%-2.8%)。
- 主要来自观察性研究的证据发现,产前使用含增效蛋白酶抑制剂的联合ART与早产风险增加相关(范围14.4%-26.1%)。
- 对于其他出生结局(低出生体重、小于胎龄儿、死产、出生缺陷、新生儿死亡),结果不一,取决于具体抗逆转录病毒药物或方案及产前治疗时机。
临床怎么用
- 2012年综述发现,避免母乳喂养和对病毒血症孕妇行剖宫产也可降低传播风险,且产前筛查能准确诊断HIV感染。
局限性
- 仍无直接证据比较产前筛查与不筛查对HIV母婴传播风险、母婴临床结局或重复或替代筛查策略检出率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prenatal screening for HIV can inform use of interventions to reduce the risk of mother-to-child transmission. The US Preventive Services Task Force (USPSTF) previously found strong evidence that prenatal HIV screening reduced risk of mother-to-child transmission. The previous evidence review was conducted in 2012. OBJECTIVE: To update the 2012 review on prenatal HIV screening to inform the USPSTF. DATA SOURCES: Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from 2012 to June 2018, with surveillance through January 2019. STUDY SELECTION: Pregnant persons 13 years and older; randomized clinical trials and cohort studies of screening vs no screening; risk of mother-to-child transmission or maternal or infant harms associated with antiretroviral therapy (ART) during pregnancy; screening yield at different intervals or in different risk groups. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. MAIN OUTCOMES AND MEASURES: Mother-to-child transmission; harms of screening and treatment; screening yield. RESULTS: Sixty-two studies were included in this review, including 29 new studies. There remains no direct evidence on effects of prenatal screening vs no screening on risk of mother-to-child HIV transmission, maternal or infant clinical outcomes, or the yield of repeat or alternative screening strategies. New evidence confirms that combination ART is highly effective at reducing the risk of mother-to-child transmission, with some new cohort studies reporting rates of mother-to-child transmission less than 1% when combination ART was started early in pregnancy (when begun in first trimester, 0%-0.4%; when begun after first trimester, or at any time if timing of ART initiation not reported, 0.4%-2.8%). New evidence on harms of ART was also largely consistent with the previous review. Evidence from primarily observational studies found prenatal combination ART with a boosted protease inhibitor associated with increased risk of preterm delivery (range, 14.4%-26.1%). For other birth outcomes (low birth weight, small for gestational age, stillbirth, birth defects, neonatal death), results were mixed and depended on the specific antiretroviral drug or drug regimen given and timing of prenatal therapy. CONCLUSIONS AND RELEVANCE: Combination ART was highly effective at reducing risk of mother-to-child HIV transmission. Use of certain ART regimens during pregnancy was associated with increased risk of harms that may be mitigated by selection of ART regimen. The 2012 review found that avoidance of breastfeeding and cesarean delivery in women with viremia also reduced risk of transmission and that prenatal screening accurately diagnosed HIV infection.
引用
- Selph SS, Bougatsos C, Dana T, et al. Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. PMID: 31184704. doi:10.1001/jama.2019.2593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。